Agios Pharmaceuticals, Inc. (LON:0HB0)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.21B |
| Revenue (ttm) | 33.32M |
| Net Income (ttm) | -298.52M |
| Shares Out | n/a |
| EPS (ttm) | -5.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,731 |
| Average Volume | 7,103 |
| Open | 28.00 |
| Previous Close | 27.50 |
| Day's Range | 27.05 - 28.55 |
| 52-Week Range | 22.40 - 61.82 |
| Beta | n/a |
| RSI | 33.12 |
| Earnings Date | Feb 12, 2026 |
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien... [Read more]
News
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO Stock News
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO Stock News
Truist Securities Initiates Coverage on Agios Pharmaceuticals (AGIO) with a 'Buy' Rating | AGIO ...
Truist Securities Initiates Coverage on Agios Pharmaceuticals (AGIO) with a 'Buy' Rating | AGIO Stock News
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper San...
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Trial Results
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Trial Results
Noteworthy Wednesday Option Activity: AGIO, VLO, AMTM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Agios Pharmaceuticals Inc (Symbol: AGIO), where a total of 24,712 contracts have traded so ...
Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility
Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click for my updated look at AGIO and reasons for downgrading it.
Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) fell 50.27%, closing at $22.62, down $22.87, following the release of topline results from its Phase 3 RISE UP trial of mitapivat in sickle cell disease.
Why Shares in Agios Pharmaceuticals Got Crushed Today
The company's pivotal Phase 3 trial hit one primary endpoint but missed another.
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Results
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Results
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged
Agios Pharmaceuticals stock shed about half its value Wednesday after the company's sickle cell disease treatment lagged expectations.
Why Is Agios Pharmaceuticals Stock Sinking Today?
Agios stock drops as mitapivat's Phase 3 trial ... Full story available on Benzinga.com
Why Is Agios Pharmaceuticals Stock Sinking Today?
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price
Oversold Conditions For Agios Pharmaceuticals
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Agios (AGIO) Phase 3 RISE UP Trial Results: Key Insights
Agios (AGIO) Phase 3 RISE UP Trial Results: Key Insights
Agios (AGIO) Trial Results Impact Market Dynamics
Agios (AGIO) Trial Results Impact Market Dynamics
Agios Pharmaceuticals (AGIO) Shares Plummet by Over 47%
Agios Pharmaceuticals (AGIO) Shares Plummet by Over 47%
Agios Pharmaceuticals (AGIO) Shares Plummet After Mixed Trial Results
Agios Pharmaceuticals (AGIO) Shares Plummet After Mixed Trial Results
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction...
Agios Pharmaceuticals (AGIO) Reports Promising Phase 3 Trial Results for Mitapivat
Agios Pharmaceuticals (AGIO) Reports Promising Phase 3 Trial Results for Mitapivat
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did n...